Our finding that YAP may inhibit ER+ breast cancer cell proliferation by blocking ERα transcriptional activity and ESR1 expression open an exciting opportunity for developing novel therapeutics to treat ER+ breast cancer patients. Here, YAP1 is linked to breast cancer.